Search Results - "Mee, Matthew"
-
1
-
2
P1254: BASELINE HLA‐DR‐RESTRICTED NEOANTIGEN BURDEN OF AML BLASTS IMPACTS ON HLA‐DR GENE EXPRESSION AT RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANT
Published in HemaSphere (08-08-2023)Get full text
Journal Article -
3
Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT
Published in Blood (13-11-2019)“…Background. Treatment failure after allogeneic haematopoietic stem-cell transplantation (AHST) using reduced-intensity conditioning (RIC) results from too much…”
Get full text
Journal Article -
4
Dose‐dense chemotherapy for untreated poor‐prognosis and relapsed germ‐cell tumours: an 18‐year experience with GAMEC chemotherapy
Published in BJU international (01-06-2020)“…Objective To report a single‐centre experience of the regimen GAMEC (granulocyte colony‐stimulating factor, actinomycin‐D, methotrexate with folinic acid…”
Get full text
Journal Article -
5
Alkylating agents as first line chemotherapy in castration resistant prostate cancer: Is survival compromised? An analysis using an updater prognostic model in castration-resistant prostate cancer
Published in Journal of clinical oncology (20-05-2015)“…Abstract only…”
Get full text
Journal Article -
6
Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy
Published in AIDS (London) (15-05-2015)“…OBJECTIVES:CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin-methatrexate/ifusamide, etoposide, cytarabine) chemotherapy is commonly used to treat…”
Get full text
Journal Article